Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Rubinstein

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
The Lancet. Oncology|February 3, 2020
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative reportTerri S Armstrong, Linda Dirven, David Arons, et al.
Investigational New Drugs|June 28, 2021
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumorsShivaani Kummar, Apurva K Srivastava, Tony Navas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2009
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignanciesShivaani Kummar, Robert Kinders, Martin E Gutierrez, et al.
Journal of the National Cancer Institute. Monographs|November 16, 2017
State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion ReportDan Xi, Ting Bao, Qi Chen, et al.
Cancer Research|July 29, 2011
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomasShivaani Kummar, Alice Chen, Jiuping Ji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2012
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomasShivaani Kummar, Jiuping Ji, Robert Morgan, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2016
Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumorsShivaani Kummar, Alice Chen, Martin Gutierrez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid TumorsSarah J Shin, Geraldine O'Sullivan Coyne, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2013
Developing safety criteria for introducing new agents into neoadjuvant trialsAngela DeMichele, Donald A Berry, JoAnne Zujewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2021
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid TumorsNaoko Takebe, Abdul Rafeh Naqash, Geraldine O'Sullivan Coyne, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
The Lancet. Oncology|February 3, 2020
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative reportTerri S Armstrong, Linda Dirven, David Arons, et al.
Investigational New Drugs|June 28, 2021
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumorsShivaani Kummar, Apurva K Srivastava, Tony Navas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2009
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignanciesShivaani Kummar, Robert Kinders, Martin E Gutierrez, et al.
Journal of the National Cancer Institute. Monographs|November 16, 2017
State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion ReportDan Xi, Ting Bao, Qi Chen, et al.
Cancer Research|July 29, 2011
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomasShivaani Kummar, Alice Chen, Jiuping Ji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2012
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomasShivaani Kummar, Jiuping Ji, Robert Morgan, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2016
Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumorsShivaani Kummar, Alice Chen, Martin Gutierrez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid TumorsSarah J Shin, Geraldine O'Sullivan Coyne, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2013
Developing safety criteria for introducing new agents into neoadjuvant trialsAngela DeMichele, Donald A Berry, JoAnne Zujewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2021
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid TumorsNaoko Takebe, Abdul Rafeh Naqash, Geraldine O'Sullivan Coyne, et al.
Pageof 6